NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals' stock experienced volatility and corporate activity in the past six months. In August 2025, NovaBay entered a $6 million securities purchase agreement with David E. Lazar, who was appointed CEO. In September 2025, the company issued a reminder regarding a pending special dividend and an upcoming annual meeting. In October 2025, NovaBay announced a one-time special cash dividend of $0.80 per share and regained compliance with NYSE American listing standards. In November 2025, the stock price was around $0.88 per share, reflecting corporate restructuring and a reverse stock split. In December 2025, the stock surged by 84.41% following FDA designations and positive market sentiment, with short interest growing by 384.3%. In January 2026, the stock reached a 52-week high of $11.49, but subsequently declined due to market developments and a pivot from liquidation to restructuring and asset sales.

Specific information regarding the seasonality of demand for NovaBay Pharmaceuticals' individual products is not extensively detailed in the provided search results. NovaBay reported record ordered product sales for its Avenova-branded eyecare products on Amazon.com in March and April 2024, with April sales increasing by over 20% compared to the previous year. The company also saw a 64% increase in online subscription-based unit sales for Avenova Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com. No specific information on demand seasonality for NeutroPhase or DERMAdoctor products was found in the provided search results.

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company based in California that develops and commercializes products for eye care, wound care, and skincare. Key products include Avenova, an eyelid and lash cleaning solution; NeutroPhase and PhaseOne, hypochlorous acid solutions for wound care; DERMAdoctor, a line of dermatological solutions (sold in March 2024); CelleRx Clinical Reset, a beauty product; i-Lid Cleanser, a foam for eyelid hygiene; and Nexagon, a solution for pre-surgical prep.

NovaBay Pharmaceuticals distributes its products across the United States, Canada, Europe, and select international markets through strategic partnerships. The company also sells its products to distribution partners in China through retailers, digital beauty channels, distributors, and online platforms like Amazon.com.

NovaBay Pharmaceuticals' brand reputation has been influenced by its financial performance and strategic changes. Analyst sentiment has been negative due to financial challenges, including operating losses and declining revenue growth. The stock's volatility has reflected investor uncertainty. The sale of the DERMAdoctor skincare business in March 2024 for approximately $1.0 million in cash was due to unmet sales and profitability projections, as part of a strategy to streamline the business and pursue more promising opportunities related to its core Avenova business.

NovaBay Pharmaceuticals, Inc. has a mix of institutional and individual owners. Major institutional owners include Vanguard Group Inc, Geode Capital Management, Llc, and State Street Corp, holding approximately 0.18% to 23.25% of the stock. Michael John Kazley is a significant individual shareholder, owning 45.08% of the company. Other notable individual insiders include Ramin Najafi, Jian Ping Fu, and Xinzhou Li. Insider ownership is reported to be around 1.68% to 187.44%.